Table 2.
Change over time in clinical biochemistry parameters during the study period.
| Toxin | Visit 1 (V1) | Visit 5 (V5) | V5-V1 |
|---|---|---|---|
| Phosphorus (mmol/L) | |||
| Placebo | 1.25 ± 0.16 | 1.26 ± 0.19 | 0.01 ± 0.16 |
| Sevelamer | 1.23 ± 0.18 | 1.20 ± 0.19 | −0.04 ± 0.20 |
| pCS (µg/mL) | |||
| Placebo | 10.34 (5.12; 21.00) | 11.69 (7.97; 25.37) | 1.97 (−1.33; 7.89) |
| Sevelamer | 11.34 (7.82; 16.44) | 11.17 (8.89; 16.13) | −0.12 (−2.70; 4.30) |
| IS (µg/mL) | |||
| Placebo | 3.45 (1.07; 5.61) | 3.46 (1.65; 9.99) | 0.38 (−0.36; 4.39) |
| Sevelamer | 4.26 (1.77; 7.35) | 3.84 (2.10; 7.49) | 0.26 (−0.85; 2.20) |
| IAA (µg/mL) | |||
| Placebo | 0.96 (0.59; 1.47) | 0.99 (0.58; 1.65) | 0.05 (−0.07; 0.16) |
| Sevelamer | 1.08 (0.57; 1.44) | 0.92 (0.57; 1.44) | −0.06 (−0.12; 0.05) |
Data are quoted as the mean ± SD for normally distributed variables, and the median (interquartile range) for non-normally distributed variables. pCS, p-cresyl sulfate; IS, indoxyl sulfate; IAA, indole acetic acid.